<DOC>
	<DOCNO>NCT02623452</DOCNO>
	<brief_summary>The study conduct participant type1 diabetes insulin injection therapy investigate body process test formulation insulin lispro effect test formulation blood sugar level . Side effect tolerability document . The study conduct two part ( Part A Part B ) achieve objective . Participants expect enroll part .</brief_summary>
	<brief_title>A Study New Type Insulin Participants With Type 1 Diabetes Insulin Injection Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Are male female participant type 1 diabetes mellitus ( T1DM ) stable multiple daily injection regimen shortacting well longacting insulin Have body mass index ( BMI ) range 18.5 33.0 kilogram per square meter ( kg/mÂ² ) , inclusive , screen Have blood pressure , pulse rate , electrocardiogram ( ECG ) , blood urine laboratory test result acceptable study Have episode severe hypoglycemia past 6 month ( require assistance treatment second party ) Have venous access sufficient allow blood sample Have provide write consent willing follow study procedure commit study duration Are currently enrol , participate within last 30 day , clinical trial type medical research judge incompatible study Have previously complete withdrawn study Have use health problem , opinion doctor , could make unsafe participate study Had blood loss 500 milliliter ( mL ) within last month Are treat continuous subcutaneous insulin infusion ( insulin pump )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>